CECMED has authorized the SOBERANA 01 clinical trial, entitled “Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity of the prophylactic FINLAY-FR-1 anti SARS–CoV–2 Vaccine Candidate in a two-dose schedule. (COVID-19) “. Recruitment will be carried out between 24 August and 30 October, in two sites in the province of Havana, until the sample of 676 healthy volunteers between 19 and 80 years old is completed. The site of the Cuban public registry of clinical trials is available at: https://rpcec.sld.cu/ensayos-por-fecha
